b-Sheet-rich a-synuclein (aS) aggregates characterize Parkinson's disease (PD). aS was long believed to be a natively unfolded monomer, but recent work suggests it also occurs in a-helix-rich tetramers. Crosslinking traps principally tetrameric aS in intact normal neurons, but not after cell lysis, suggesting a dynamic equilibrium. Here we show that freshly biopsied normal human brain contains abundant aS tetramers. The PD-causing mutation A53T decreases tetramers in mouse brain. Neurons derived from an A53T patient have decreased tetramers. Neurons expressing E46K do also, and adding 1-2 E46K-like mutations into the canonical aS repeat motifs (KTKEGV) further reduces tetramers, decreases aS solubility and induces neurotoxicity and round inclusions. The other three fPD missense mutations likewise decrease tetramer:monomer ratios. The destabilization of physiological tetramers by PD-causing missense mutations and the neurotoxicity and inclusions induced by markedly decreasing tetramers suggest that decreased a-helical tetramers and increased unfolded monomers initiate pathogenesis. Tetramer-stabilizing compounds should prevent this.
a-S ynuclein (aS) accumulates as insoluble protein aggregates in Lewy bodies and Lewy neurites, the hallmarks of familial and sporadic Parkinson's disease (PD) and several other fatal diseases 1 . aS missense mutations, copy number variants and upregulated expression have each been associated with familial PD [2] [3] [4] [5] [6] . Unexpected findings from our 7 and one other laboratory 8 suggested that aS can occur physiologically not only as unfolded monomers but in large part as multimers, principally tetramers, that have a-helical conformation and resist aggregation. Crosslinking analyses of endogenous aS in living cells 9 supported this new model: in primary neurons and other cells, cell-penetrant crosslinkers disuccinimidyl glutarate (DSG) or dithiobis(succinimidyl propionate) (DSP) trapped aS in abundant species larger than monomer, especially at B60 kDa, the size of four N-acetylated aS monomers (4 Â 14,502 daltons ¼ 58,010 daltons). Known monomeric proteins (for example, cytosolic tubulin; Parkin; Ran) were not altered by the crosslinking, while known multimeric proteins (for example, DJ-1; voltage-dependent anion channel (VDAC); dynamin-related protein 1 (Drp1)) were trapped as the expected multimers. We systematically ruled out artifactual induction of these multimers by the crosslinking, abnormally migrating monomers, and hetero-oligomers with other proteins 9 . In addition to the major B60 kDa apparent tetramer (aS60), smaller amounts of endogenous aS were trapped as multimers of B80 and B100 kDa (aS80 and aS100) that have the same isoelectric point as the monomer and may be conformers of the tetramer or higher-order multimers (for example, hexamer and octamer) 9 . All multimers were depolymerized to monomers when crosslinkers were applied after cell lysis, unless the lysis was done at high protein concentrations ('molecular crowding') 9 . Other endogenous multimeric proteins did not show this striking cell lysis sensitivity, except for the homolog b-synuclein (bS) 9 . These findings led us to postulate that dynamic intracellular populations of aS monomers and metastable multimers co-exist normally 7, 9 . Such a dynamic equilibrium has been proposed for well-known tetrameric proteins such as p53 (refs 10,11) and haemoglobin 12 .
Some labs subsequently published data they interpreted as supporting the earlier model of aS existing as natively unfolded monomers in cells and brain. However, these studies either did not employ crosslinking of intact cells 13 or considered any crosslinked oligomeric aS to be non-specific 14 . The possiblilty that the endogenous multimers we trap by crosslinking are pathological is made highly unlikely by biophysical evidence of ahelical tetramers (B58 kDa) purified natively from normal human cells 7, 15 , the abundance of trapped tetramers in healthy, non-transfected cells 9, 16 and the trapping in analogous tetrameric forms of the non-pathogenic bS and of aS lacking its aggregationprone NAC domain 9 .
This unresolved but central debate about the existence and biological relevance of aS tetramers led us to use additional approaches. Here we first examined aS in freshly biopsied normal human brain, the most physiologically relevant source of the protein. To do so, we developed a method for intact-cell crosslinking of fresh brain tissue that reveals the endogenous state of aS. Second, we asked whether aS missense mutations that unequivocally cause PD might alter the tetramer:monomer ratio in human neurons. Despite almost two decades of study, the fundamental mechanism by which these mutants initiate aS aggregation, Lewy body formation and PD remains unclear. To this end, we rigorously standardized our intact-cell crosslinking method until it was precise enough to quantify accurately the effects of each of the five PD-causing aS missense mutations. And third, we applied fluorescent protein complementation to independently confirm our key findings in living cells. Using both live-cell methods (chemical crosslinking and yellow fluorescent protein (YFP) complementation), we found that PD-causing aS missense mutations partially shifted cellular aS from tetramers/ multimers to monomers. This shift became prounced when we amplified the effect of the E46K PD mutation by making similar E-to-K substitutions in two adjacent KTKEGV repeat motifs, leading to marked reduction of cellular tetramers, decreased aS solubility, formation of round inclusions and cytoxicity.
Results
Abundant aS tetramers occur in normal human and mouse brain. We previously reported that the crosslinking pattern of endogenous aS in intact cells differed from the stochastic crosslinking of recombinant monomeric aS in vitro, in that the former strongly favoured the trapping of tetramers, with few or no intermediate dimers or trimers 9 . We now sought to crosslink aS in its endogenous state in normal brain tissue. We achieved this by mincing fresh brain with a mechanical tissue chopper, performing gentle centrifugal washes on the intact tissue pieces and then subjecting only these washed brain bits to crosslinking, thereby largely avoiding the tetramer-destabilizing effects of breaking cells open 9 (see Methods and Supplementary Fig. 1 ). We applied this protocol to an optimal source of physiological aS: a fresh brain biopsy (elective surgery for focal epilepsy) from the cerebral cortex of a young patient free of any neurodegenerative process. After the mincing and centrifugal washes, we applied DSG (1 mM solution) at an increasing ratio of volume of crosslinking solution to brain protein, or else applied the reducible crosslinker DSP (2 mM solution) at a fixed ratio. The crosslinked tissue bits were then sonicated and separated (100,000 g spin) into PBS ('cytosol') and Triton X-100 (TX-100; 'membrane') fractions. Immunoblotting confirmed efficient crosslinking had occurred, as the cytosolic protein DJ-1 and the transmembrane protein VDAC were each trapped in their native dimeric states in a DSG dose-dependent manner (Fig. 1a, upper panels) . As before, we fixed blots in paraformaldehyde 17 to improve aS retention during blot washing 16 . Total aS levels were compared using the DSPcrosslinked-and-reduced sample, which we had shown previously was optimal for quantifying total cellular aS levels in crosslinking studies 16 . Enrichment of DJ-1 and absence of VDAC and synaptobrevin-2 established cytosol purity (Fig. 1a , upper panels). Immunoblotting confirmed our earlier findings in cultured neurons 9 : aS was detected in the biopsied human brain primarily as tetramers (aS60) and related multimers (aS80, aS100) by mAbs Syn1 and 15G7 (Fig. 1a) . Antiserum C20 preferentially detected monomers, although its aS60:14 ratio was still 1:1 versus 2:1 using mAb Syn1 (Fig. 1a, lower panels) . Including the aS80 and aS100 multimers with the aS60 tetramers showed the clear preponderance of aS multimers over monomers (3:1) in normal human brain. Similar to our findings in primary neurons 9 , the multimers were found overwhelmingly in the human brain cytosol (Fig. 1a , lower panels). In the membrane fraction, virtually only monomer was detected.
Next, we obtained closely similar results in minced fresh wildtype (WT) mouse brain using antibodies to aS and, importantly, to bS (Fig. 1b) . Applying increasing DSG concentrations to mouse brain bits, human erythroleukemia (HEL) cells (Fig. 1c) or cultured primary neurons (Fig. 1d) did not completely trap aS at discrete multimeric positions. Instead, aS60 levels plateaued at a certain DSG concentration; further depletion of free 14 kDa monomer only added to high molecular weight (HMW) smears of aS immunoreactivity, probably the result of non-specific overcrosslinking (Fig. 1c) . Similar to aS, known tetrameric proteins such as p53 (refs 18,19) and Drp1 (ref. 20) exhibited HMW smears as well as oligomeric bands higher than their expected tetramer positions, especially at high DSG (Fig. 1d) . Interestingly, crosslinking of the known tetrameric protein p53 was similar to aS in that intermediate dimers were of low abundance, whereas Drp1 showed a more ladder-like oligomer pattern (Fig. 1d) . Monomeric cytosolic proteins such as Parkin, Ran and casein kinase 1a were always unaffected by crosslinking, as expected ( Fig. 1d; Supplementary Fig. 2 for uncropped blots). Compared with the known tetrameric proteins, crosslinking of the known dimeric proteins DJ-1 or VDAC led to less HMW smears (Fig. 1a) . These multiple control proteins support the ability of our crosslinking protocol to detect endogenous tetramers of proteins like p53, aS and bS in intact cells and brain tissue and not to induce artifactual oligomers of known monomeric proteins.
These data support a model in which aS exists predominantly as cytosolic multimers at steady state, while a smaller cytosolic portion and most aS on membranes (together representing a minority of total cellular aS) appears to be monomeric. To address the localization of intracellular aS without disrupting the cell membrane, we performed immunofluorescence microscopy ARTICLE of endogenous aS in primary rat neurons (Fig. 1e) and also virally expressed WT aS in human M17D neuroblastoma cells, which have very low endogenous aS (Fig. 1f) . In both cell types, aS strongly co-localized with transiently expressed red fluorescent protein (RFP; Fig. 1e ) or green fluorescent protein (GFP; Fig. 1f ), which are known to be soluble and cytoplasmic. Next, we transfected M17D cells with aS fused to either intact YFP (Fig. 1g , second column) or else split YFP, that is, we co-transfected VN-aS (N-terminal half of Venus-YFP fused to N-terminus of an aS monomer) and aS-VC (C-terminal half of Venus-YFP fused to the C-terminus of an aS monomer) (Fig. 1g, third column) . YFP complementation assays monitor the interaction of intracellular proteins in real-time and are based on the principle that interactions of the tagged protein (here aS) bring VN and VC into close proximity, leading to Venus-YFP complementation and thus fluorescence detectable by microscopy or plate reader. The living cells showed strong YFP fluoresence that co-localized with free cytosolic RFP and was distributed similarly to YFP alone (Fig. 1g, first column) . These controls confirmed previously reported fluorescent complementation of WT aS using such an assay 21 and underscored the cytosolic nature of these multimeric species. VC alone (C-terminal half of Venus-YFP) did not complement with VN-aS, ruling out an intrinsic affinity of VC and VN as responsible for the observed complementation ( Fig. 1g : fourth versus fifth columns).
Two independent methods to quantify cellular aS multimers.
To standardize the fluorescent complementation assay for repeated measurements, we generated a VN-aS stable M17D line, enabling highly consistent complementation signals by transiently transfecting this line with various WT or mutant aS-VC constructs. Using an automated plate reader to quantify YFP fluorescence, we found that VN-aS complementation with VC-tagged Ran (a control cytosolic protein) was negligible compared with aS-VC (quantified in Fig. 1h : first two lanes). Additional controls for signal specificity, including the need for specific fusion positions of aS relative to the fluorescent protein fragments and the negligible self-complementation of the split YFP fragments alone (see Fig. 1g , fourth lane), were reported previously for aS GFP-complementation 22 and YFPcomplementation 21 . Despite the rapid and strong self-interaction we detected for WT aS (Fig. 1h , second lane) and the widespread use of fluorescent protein complementation to study native protein interactions, the aS field has heretofore interpreted such complementation as indicative of pathological oligomerization, given the long-standing assumption that the normal state of cellular aS is monomeric 14 . We analysed the effects of the known familial PD-linked missense mutations and observed significant reductions of fluorescent complementation for the E46K, G51D and A53T mutants versus WT aS (Fig. 1h) . A30P complementation was similar to WT, but we consistently observed increased expression of A30P and also G51D by immunoblotting ( Fig. 1h ; top western blot), indicating that these two variants lead to enhanced aS-VC levels, and thus normalized values might detect reduced complementation for A30P as well. The decreased aS complementation seen here with three of the four familial PD (fPD) mutants studied supports the physiological nature of the multimers (otherwise, fPD mutations should increase complementation). There are certain disadvantages of this system: aS is modified by large tags; determining the sizes of the multimers is not possible; YFP complementation may be irreversible 23 and thus disturb multimer:monomer equilibria; and crosslinking trapped abundant dimers but less tetramers of VN-aS þ aS-VC ( Supplementary Fig. 3 ), a pattern different from endogenous (untagged) aS. The latter result may be due to the relative steric hindrance we previously reported for tagged aS 9 and/or decreased access by the crosslinker into any tagged tetramers.
In light of these disadvantages of relying solely on YFP complementation for aS multimer quantification, we sought to rigorously standardize our intact-cell crosslinking protocol as a second independent method (Methods). We transfected M17D cells with increasing amounts of WT aS cDNA and applied a constant DSG amount at 40 hr post transfection. By confirming equal DJ-1 dimer:monomer ratios in the same cytosols as an internal standard for crosslinking efficiency in all experiments (Fig. 2a, left panel) , we observed a constant aS60:14 ratio across the range of aS expression levels we tested (Fig. 2a,  right panel) . Plotting the relative intensities of aS60 and aS14 in multiple independent experiments revealed a highly linear relationship of the two (R 2 ¼ 0.97) (Fig. 2b) , and the apparent aS60:14 ratio (using Syn1 for detection) was a constant 1.2 in this series of experiments (Fig. 2c) . (For the three multimer species combined (aS60 þ 80 þ 100), their ratio to monomer was 2.8.) We next tested the reducible crosslinker DSP (Fig. 2d ) and again found a highly linear correlation (R 2 ¼ 0.97) between aS60 and aS14 levels (Fig. 2e) , here with a constant ratio of 0.9 (Fig. 2f) . Analysis of aS80 and aS100 revealed a similarly linear ratio to monomer across this range of aS expression ( Supplementary  Fig. 4 ), but we focused our further analyses on the aS60 tetramer as our standard readout for four reasons: an independent biophysical method (analytical ultracentrifugation) originally revealed that the principal a-helical multimer purified from fresh human erythrocytes under non-denaturing conditions has a molecular weight of 58 kDa, exactly that of four monomers 7 ; all of our many intact-cell crosslinking experiments to date identified aS60 as the most abundant and consistent cellular multimer 7, 9, 16 ; mass spectrometry confirmed here that aS60 contains only aS ( Supplementary Fig. 5) ; and for quantification, aS60 is representative of all physiological aS multimers we detect (for example, Supplementary Fig. 4 ). The constant aS60:14 ratio across a wide range of cellular aS levels (Fig. 2c,f) was important for our subsequent analysis of fPD mutations: even if aS expression levels differ somewhat among mutants for biological or technical reasons, comparisons of the ratios should be meaningful.
The linear correlation of aS60 and aS14 levels across the expression range we tested suggests that these levels are theoretically in the same range as the apparent equilibrium constant. However, protein assembly systems in living cells are not in a true equilibrium but rather in a dynamic flux influenced by factors like biosynthetic and degradation rates and changes in subcellular localization. In this context, it is noteworthy that the aS concentrations we obtained by transient expression in human neuroblastoma cells (0.15-1.65 ng aS per mg of total cytosolic protein when using a range of 1-8 mg DNA transfected into 6-cm dishes) did not exceed the aS concentration in lysates of freshly biopsied human brain (1.8 ng mg À 1 ), as quantified by aS enzymelinked immunosorbent assay (ELISA) and confirmed by immunoblotting (Fig. 2g) . Indeed, our measured concentrations are lower than the endogenous neuronal concentration in brain because brain lysate includes proteins from many non-neuronal cells having low aS. Overall, we achieved generally similar PBSsoluble (cytosolic) aS levels when we repeatedly expressed WT or five aS mutants in M17D cells (Fig. 2h) . Despite a putative function in membrane vesicle homeostasis, aS has been reported to be predominantly cytosolic 13, 24, 25 , consistent with our data in primary neurons 9 and human brain (Fig. 1a) . In accord, our ELISA detected a very high portion (485%) of cellular aS in the cytosol; the TX-100-soluble membrane fractions contained minor amounts (o15%) (Fig. 2i) . Highly insoluble cellular fractions (that is, sequential 2% SDS and 88% formic acid extracts) contained very minor aS amounts, with no obvious effects of the 5 fPD mutations. Our ELISA was validated as detecting both normal and aggregated forms of aS ( Supplementary Fig. 6 ). Western blots likewise detect only minor aS amounts in the 2% SDS-soluble fraction 9 . These relative distributions across fractions were true for both WT and fPD-mutant aS even after intact-cell crosslinking (Fig. 2i) . Therefore, in our many iterative experiments below, we focused on the PBS-soluble (cytosol) major fraction but included some analyses of the TX-100-soluble minor fraction.
fPD missense mutations lower the aS multimer:monomer ratio. To determine whether the fPD-causing aS mutations A30P, E46K, G51D and A53T (tested by fluorescence complementation in Fig. 1h ) and the recently discovered H50Q 26 alter the tetramer: monomer ratio in intact cells, we initially transfected human M17D neural cells with WT aS or one of these five fPD mutants and performed DSG crosslinking and quantitative western blots of the cytosols (Fig. 3a, top panel) . Trapping of the endogenous DJ-1 dimer confirmed equal crosslinking across samples (Fig. 3a , middle panel; Supplementary Fig. 7 for uncropped blots). We identified Syn1 as the optimal antibody to detect aS because it is widely used and commercially available (unlike 15G7 or our 2F12), it does not show a preference for monomeric or multimeric aS (C20 reacts more with monomers, and 211 and LB509 do not detect multimers 9 ), and it gave the clearest blots of the aS transfectants. Thus, statistical analyses of the experiments that follow used Syn1, but importantly, other aS antibodies confirmed all key findings in this section. In many iterative experiments, we detected similar or slightly reduced aS expression levels for the mutants versus WT, except for A30P and G51D, which showed variable but modestly higher aS levels ( Fig. 3a,b ; compare with Fig. 1h ). These variations were well within the aS expression range found not to alter the aS60:14 ratio (see Fig. 2 ). Densitometry of multiple independent experiments after intact-cell crosslinking with DSG (exemplified by Fig. 3a) or DSP (exemplified by Fig. 3b ) and a meta-analysis of the two agents revealed highly significant decreases (Po0.01, n ¼ 25, one-sided analysis of variance (ANOVA), percentages ± s.d.; statistical details in Fig. 3 legend and Methods) in the aS60:14 ratio for A30P (77.5±15.5% of WT, that is, a 22.5% decrease), E46K (61.7 ± 10.1% of WT, a 38.3% decrease), G51D (47.8±10.0% of WT, a 52.2% decrease) and A53T (66.5 ± 10.4% of WT, a 33.5% decrease). H50Q caused a smaller (83.7±14.4% of WT, 16.3% decrease) but still significant (Po0.05) reduction (Fig. 3c, upper panel) . The same significant effects were observed when the ratio of all multimeric species (aS60 þ 80 þ 100 combined) relative to aS14 was analysed (Fig. 3c , lower panel). We observed decreases versus WT in aS60 levels (Fig. 3d , upper panel) or aS60 þ 80 þ 100 levels ( Fig. 3d , lower panel) for E46K, G51D and A53T, while the aS60 levels for A30P and H50Q were not significantly changed from WT. aS14 monomer levels increased significantly versus WT for A30P and G51D (Fig. 3e) . Strikingly, engineered compound fPD mutants '3x' (H50Q þ G51D þ A53T) and '4x' (H50Q þ G51D þ A53T þ E46K) further decreased the aS60:14 ratio compared with G51D alone, causing clear-cut elevations of free monomers (Fig. 3f,g ). We then tested the overall findingreduction of relative cellular multimer levels by fPD mutants-in a system that is closer to the steady-state situation in neurons, ARTICLE namely stable lentivirus transduction of the neural M17D cells with WT, E46K or G51D aS. The fPD mutants again reduced the cytosolic multimer:monomer ratio (due to both a decrease in multimers and increase in monomers versus WT), and sequential extractions again showed that non-cytosolic fractions contained only minor aS amounts ( Supplementary Fig. 7 ).
Decreased multimers in hA53T mice and A53T iPSC neurons. Our method of crosslinking fresh, minced brain tissue ( Fig. 1 ; Supplementary Fig. 1 .; Methods) presented the opportunity to analyse the effects on aS tetramers of a PD-causing aS mutation expressed in mouse brain. We examined the brains (Fig. 4a) of young aS-/-mice expressing relatively low levels of human WT E46K  H50Q  G51D  A53T  wt  A30P  E46K  H50Q  G51D  A53T  wt  A30P  E46K  H50Q  G51D  A53T   DSG  DSG/DSP  DSP   wt  A30P  E46K  H50Q  G51D  A53T  wt  A30P  E46K  H50Q  G51D  A53T  wt  A30P  E46K  H50Q  G51D  A53T   DSG  DSG/DSP  DSP   wt  A30P  E46K  H50Q  G51D  A53T  wt  A30P  E46K  H50Q  G51D  A53T  wt  A30P  E46K  H50Q  G51D (hWT) or A53T (hA53T) aS 27 . Comparing total aS levels among samples using both untreated and DSP þ b-mercaptoethanol (bME)-treated samples confirmed that DSP þ bME facilitates the quantitative detection of total aS immunoreactivity on blots (Fig. 4b) 16 . Consistent with the brain expression data reported for these mouse lines 27 , PBS extracts ('cytosol') of the hA53T brain showed somewhat lower total aS than the hWT brain (Fig. 4b ). The aS60:14 ratio was significantly reduced (Po0.05, Student's t-test, n ¼ 9) in hA53T brain cytosols (Fig. 4c) , due to a greater decrease in aS60 tetramer than aS14 monomer in hA53T versus hWT (Fig. 4d) . To show that this ratio difference was not an artifact of the somewhat lower total aS levels in the hA53T brain, we included longer (L) exposures for hA53T that were adjusted to match the aS14 intensity of the hWT sample (Fig. 4b: 'expo. L'). Densitometry on both exposures led to closely similar results of 420% reduction, namely, an aS60:14 ratio for hA53T versus hWT of 69.4±20.2% ('S') or 75.3 ± 20.1% ('L'), (Po0.05, n ¼ 9, Student's t-test), with no significant difference in this result between the two exposures (Fig. 4c) . This lower aS60:14 ratio in the hA53T mouse brain cytosol was consistently observed with Syn1 and confirmed with antibodies 15G7 and C20 (Fig. 4e) . As expected, the hA53T aS60:14 ratio was also reduced when we analysed total lysates of whole mouse brain (that is, homogenizing the crosslinked tissue directly in TX-100) (Fig. 5f ). In the membrane (TX-100) fractions, we found no significant reduction of aS14 monomer levels in hA53T versus hWT; as in the fresh human brain (Fig. 1a) , tetramers/multimers were very low in abundance in this fraction and were almost undetectable for hA53T (Fig. 4g,h ).
Given that the human A53T mutation corresponds to rodent WT aS at that codon, possibly masking pathological effects in the mouse brain, we sought to validate the A53T effect directly in a disease-relevant human cell model. To preclude experimental variation resulting from random genomic integration of a transgene, we initially used human embryonic stem cells (hESCs) that express human aS from a defined genetic 'safe habour' locus under the control of a doxycyline (Dox) inducible promoter, using a zinc-finger nuclease (ZFN)-based gene editing strategy 28, 29 (Methods). These hESCs carrying either WT or A53T aS were differentiated into neural precursor cells (NPCs), which have low endogenous aS expression (Methods). Adding Dox for 4 days produced robust expression of the WT and A53T transgenes (Fig. 5a ). These human NPCs closely reproduced our mouse brain observation: a B30% lower aS60:14 ratio for A53T than WT (67.9 ± 9.1% of WT, n ¼ 6, Po0.05, Student's t-test; Fig. 5b) , and a reduction in total A53T aS immunoreactivity (Fig. 5a ) due to lower aS60 levels (Fig. 5c) . Moreover, this NPC system indicated that neither long expression (44 days) nor full neuronal differentiation is necessary for aS tetramer formation.
We then conducted quantitative analyses in neurons differentiated from an induced pluripotent stem cell (iPSC) line of a living PD patient harbouring the A53T mutation versus its corrected isogenic line (WT corr ; ref. 30; Methods). Abundant microtubule-associated protein 2 (MAP2) expression in both lines indicated equal neuronal differentiation (Fig. 5d, left panel) . Following intact-cell crosslinking and sequential extraction, the cytosols showed similar crosslinking efficiency based on DJ-1 dimer levels, and we again detected lower aS60:14 ratios for A53T than WT using three aS antibodies (Fig. 5d-f) . Quantification of Fig. 5f ). This was again due to a lower aS60 level (Fig. 5g,h ), a finding entirely consistent across antibodies and experiments. In a similar way, we confirmed the effect of E46K (Fig. 5i) , as initially determined in M17D cells (Fig. 3) , in neurons derived from isogenic hESCs in which the E46K mutation had been inserted by genome editing 30 : the aS60:14 ratio was reduced by 435% (61.1 ± 8.7% of WT, Po0.01, n ¼ 4, Student's t-test; Fig. 5j ), mostly due to strongly reduced tetramer levels (Fig. 5k,l) . Interestingly, the decrease in tetramers in these lines was closely similar to that seen in the earlier systems, even though these human neurons are heterozygous for A53T or E46K aS, suggesting a possible dominant-negative effect on tetramer formation. Amplifying E46K leads to less multimers and induces toxicity. Whereas A53T occurs in a unique stretch within aS, E46K is located within a canonical KTKEGV motif, which occurs at least six times in aS with slight variation (Fig. 6a) , resembles motifs in apolipoprotein A1, and may facilitate interactions with lipids 31 . These facts suggested an intriguing opportunity to validate our central hypothesis: we reasoned that the multimer-destabilizing effect of E46K (Figs 1h and 3 ) might be amplified by analogous mutations in other KTKEGV motifs. We analysed aS constructs with one, two or three E46K-like substitutions, targeting the highly conserved KTKEGV motifs #3 and #5 flanking the fPD E46K-harbouring motif #4 (Fig. 6a) 
Transfected M17D/VN-αS transfected M17D cells revealed a striking 'dose-dependent' destabilization of aS60 by each additional E-K substitution, with the triple-K mutant almost abolishing cellular tetramers ( Fig. 6b; Supplementary Fig. 9 for all uncropped blots in this section). To exclude an artificial effect of these lysine substitutions on the lysine-directed DSG crosslinking reaction itself, we expressed analogous arginine mutations (that is, 1R ¼ E46R, and 3R), which also change the negative charge to positive but do not offer additional sites for our lysine-directed DSG crosslinker. Like E-K, the E-R substitutions in these three adjacent aS repeat motifs caused similar sharp reductions of the aS60:14 ratio (Fig. 6c) . Importantly, the aS14 monomer remained well expressed for all constructs. We confirmed these findings in independent pools of lentivirus-transduced E-K M17D cells (Fig. 6d) , obtaining closely similar decreases in the aS60:14 ratio despite some variability in total aS expression. The stepwise decrease in tetramer level was associated with a stepwise increase in monomer level, strongly supporting our overall hypothesis. These consistent decreases in multimer formation documented by crosslinking offered an opportunity to independently quantify the E-K effect using our Venus-YFP complementation assay (Fig. 1g,h ) and thus further cross-validate both methods. As a first step, we used the same protocol as in Fig. 1h by transfecting WT or E-K mutated aS-VC constructs into our VN-aS WT stable M17D line, followed by automated quantification of YFPfluorescence. We observed a stepwise decrease in aS complementation with each additional E-K substitution, and with no consistent differences in total aS expression as detected by immunoblotting (Fig. 6e) . Next, we used the opposite setup, introducing the E-K mutants into VN-aS constructs and coexpressing them in M17D cells with stable WT aS-VC. To quantify the resultant complementation, we chose areas from deidentified ('blinded') cultures having closely similar cell densities by bright-field microscopy and examined many fields by fluorescence microscopy (Fig. 6f, upper panels) . As always, stronger fluorescent signals (white) indicate greater complementation. There was a striking stepwise decrease of fluorescence with each additional E46K-like substitution in the repeat motifs (Fig. 6f) . Immunoblotting with different aS and control antibodies excluded differences in protein levels (Fig. 6f, lower  panels) , and expressing aS-VC alone produced no fluorescence (Fig. 6f) . In primary rat neurons, co-expression of aSKKK-VC and VN-aSKKK led to very low complementation that was virtually below detection limit, while both variants were clearly expressed, as shown by immunofluorescence using human aS-specific antibody 15G7 (Supplementary Fig. 10 ).
The analysis of single fPD mutants in acute cell culture has not produced consistent effects as regards their cytotoxicity 31 , in keeping with fPD being a very gradual disease of relatively late onset, but we reasoned that our 'amplified' E46K tetramerabrogating effect might produce measurable cytotoxicity in cultured neural cells. We thus expressed WT aS and all three E-K variants (1, 2 and 3K) in human M17D cells and observed a highly significant stepwise reduction in cell viability with each E-K substitution added to E46K, as documented by both trypan blue exclusion and an adenylate kinase release assay (Methods); the effect of E46K alone versus WT was noticeable but relatively weak (Fig. 6g, upper two panels) . Importantly, these decreases in cell viability were accompanied by opposite increases in cleaved PARP, a widely used indicator for the activation of apoptosis (Fig. 6g, third panel) , and again the single E46K alone had a weak but noticeable effect. These results were not due to differences in expression levels (Fig. 6g, fourth and fifth panels) . When we asked whether this increase in neurotoxicity was paralleled by changes in aS solubility, we found increased total aS immunoreactivity in PBS-insoluble fractions such as the TX-100-soluble fraction (Fig. 6h) with each additional E-K substitution, starting with just 1K. Moreover, in live M17D cells, YFP-tagged aS-KKK showed a strong tendency to form round cytoplasmic inclusions (in 79 ± 8.1% of cells; Fig. 6i ), and this was weaker (23.5 ± 5.9% of cells) but still highly significant (Po0.01) in aS-KK and less so but still noticeable (4.5 ± 1.0% of cells; P40.05) in aS-K versus aS-WT (2.3 ± 0.6%), whereas the co-transfected soluble RFP control protein remained uniformly cytosolic (Fig. 6i) . Importantly, we obtained highly similar results when we expressed untagged WT aS and the E-K mutants in primary rat neurons (DIV 12) and quantified the prevalence of cells harbouring discrete round inclusions in cell bodies and/or neurites (Fig. 6j) .
Discussion aS accumulates in b-sheet-rich fibrils in numerous neurodegenerative diseases. For nearly two decades, aS was believed to exist normally as a natively unfolded, 14.5 kDa monomer 14, 32 , and most papers on aS have emphasized this assumption in their introductions. In contrast, we recently reported that cellular aS can occur physiologically in partially a-helical, aggregationresistant B60 kDa tetramers 7 and that these may be in a complex equilibrium with monomers also normally present in neurons 9 . This unexpected finding has been controversial 13, 14 . Here we document that aS exists as a B60 kDa tetramer in fresh, normal human brain tissue. Then, we show in multiple systems that all fPD-causing aS missense mutations significantly decrease tetramer:monomer ratios in neural cells, including in human neurons derived directly from a patient with the A53T mutation or WT human neurons genetically engineered to express E46K. This invariant effect by mutations known to unequivocally cause clinical PD strongly suggests that a tetramer-to-monomer destabilization facilitates subsequent pathological aggregation of monomers into disease-mediating assemblies. We validate this concept in Fig. 6 : by inserting the PD-causing mutation at E46K into the analogous sites of first one and then two adjacent repeat motifs, we simultaneously link a stepwise decrease in tetramers/ multimers and increase in monomers inside neurons (quantified by two methods) to a stepwise increase in neurotoxicity (quantified by three independent assays) and accumulation of aS in round cytoplasmic inclusions. This elucidation of a genotype-to-phenotype relationship for five fPD mutations, the initial pathogenic mechanisms of which have remained unclear, provides a compelling new model for how a-synucleinopathy can be initiated in PD and related disorders.
Each fPD-causing mutation reduced the intracellular aS60:14 ratio by 10-40% depending on the mutant, and engineered triple (H50Q-G51D-A53T) and quadruple (triple þ E46K) fPD mutants produced even larger decreases, with sharp rises in free monomers. YFP complementation (analysed in a blinded fashion) showed highly significant effects of aS mutations in the same direction. We confirmed the fPD-mutant effect in the most relevant available systems: aS-/-mouse brain having low transgenic expression of human A53T aS, iPSC-derived neurons obtained from an A53T patient and engineered E46K hESCderived neurons. This consistency across multiple cell/tissue sources and with two distinct techniques validates the mutational effects. The multimer-destabilizing effect and concurrent slight neurotoxicity of the E46K fPD mutation (Fig. 6g) was significantly 'amplified' by adding just one or two E46K-like mutations in the adjacent KTKEGV motifs. Our observation that intact six-residue repeats contribute to the normal aS tetrameric structure is of interest because analogous repeats occur in apolipoprotein A1 (ref. 31) , which forms native low-n multimers in its lipid-free state [33] [34] [35] and was crystallized as a tetramer 36 . Our multiple cellular and brain tissue experiments suggest that all of the clinical missense mutations destabilize the physiological tetramer, eventually leading to higher relative levels of unfolded monomer, the form believed to be the starting point for pathological aS aggregation 37 . Our results across the five fPD mutations showed a destabilization of tetramers most clearly, while the accumulation of monomers in our short-term experiments varied and achieved significance for A30P and G51D (Fig. 3e) . Neurons are likely to compensate for unfolded aS monomers by degrading or clearing them in the short-term, but over longer periods or a human lifetime, this may not suffice to control the potential aggregation of excess monomers arising chronically from destabilized tetramers. In this context, we previously found that the native, helical tetramer purified from WT human erythrocytes showed no aggregation upon extended in vitro incubation, whereas unfolded monomers readily aggregated into b-sheet-rich fibrils (see Fig. 3d in ref. 7) .
Two technical advances over our previous protocol for intactcell crosslinking 9 enabled these new findings. First, we developed a procedure to efficiently crosslink intracellular proteins in fresh brain samples that largely excludes broken cells. The latter step is key to studying aS because upon cell lysis, tetramers of aS or bS are depolymerized and can no longer be trapped quantitatively in their in vivo state 9 . Applying this new protocol to human brain immediately after biopsy confirmed the major observations of our intact-neuron crosslinking 9 : an abundant aS60 species (plus some aS80 and aS100 multimers) in the PBS-soluble fraction, with only minor and primarily monomeric aS in the membrane fraction. The fresh, normal human brain showed tetramers and monomers but essentially no intermediate dimer and trimer species, entirely distinct from what would be seen with artifactual (non-specific) crosslinking of the highly abundant aS protein, which in unfolded recombinant form produces a stochastic ladder of monomers4dimers4trimers4tetramers and so on. (see Fig. 4c  in ref. 9 ). Of note, the known tetrameric protein p53 behaved similarly to aS in both our (Fig. 1d) and previous 18 crosslinking assays: pronounced tetramers, few dimer or trimer intermediates, some apparent higher assemblies, and smears on overcrosslinking. And as before 9 , known monomeric proteins were not made into artifactual oligomers by our crosslinking (Fig. 1) . Our new tissue protocol also revealed abundant aS tetramers in normal mouse brain, and the non-pathogenic homolog bS showed a closely similar pattern. Collectively, these results substantiate that the cellular tetramer detected by crosslinking is a physiological, not pathological or artifactual, assembly.
Second, by stringently standardizing our protocol to make it quantitative, we addressed novel questions relevant to PD pathogenesis: are cellular tetramer:monomer ratios affected by aS expression levels and by PD-causing aS mutations? We generated data indicating that (a) the cellular tetramer:monomer ratio is constant over a relatively wide range of aS expression levels that were similar to but always somewhat lower than those in human brain tissue; and (b) mutations which cause fPD shift the ratio away from the tetramer. The steady rise in tetramer levels with increasing aS expression (Fig. 2) suggests that physiological tetramerization is either an intrinsic feature of the aS polypeptide chain or any transacting co-factors needed for tetramer assembly and stabilization (for example, membrane vesicles, free lipids and so on) are not limiting in our cells at these aS expression levels.
Two recent studies confirm the existence of physiological multimers (including tetramers) in neurons 21, 38 , and one of these 21 provides functional evidence that a portion of aS multimers can localize to synaptic vesicles, cluster them and prevent their exocytosis, which could downregulate neurotransmitter release. Nonetheless, data from our and several other 7,8,15,39 labs suggest that native aS multimers are mainly present in the cytosol. Westphal and Chandra 15 confirmed the purification of a-helical aS assemblies from erythrocytes using our methods and underscored their soluble nature. A study on g-synuclein suggested that this aS homolog is tetrameric unless it binds to heterologous binding partners or membranes 40 , in agreement with our finding that cytosolic but not membraneassociated aS molecules are recovered as multimers. Wang et al. 8 reported NMR analyses of an N-terminally modified aS construct expressed in E. coli and purified under non-denaturing conditions that formed a-helical tetramers. Their CD spectroscopy of WT and fPD recombinant proteins revealed decreasing a-helical content in the order WT4A30P4A53T4E46K, closely resembling the relative order of the aS60:14 ratios in our assays (see Supplementary Fig. 11 ). The reported ages of symptom onset in humans carrying fPD missense mutations may agree in general with the relative decrease in our aS60:14 ratios. G51D causes very early onset PD similar to aS triplication 41, 42 , while symptoms from H50Q and A30P begin somewhat later 3, 26, 43 ; we find the greatest lowering of the tetramer:monomer ratio for G51D and the least for A30P and H50Q (Fig. 3) .
Tetramers and monomers are likely to be in a complex dynamic equilibrium in living cells, as proposed for p53 (refs 10,11) . The aS60 species (which we confirmed here by mass spectrometry to contain only aS on purification ( Supplementary Fig. S3 )) was representative of the aS80 and aS100 species ( Supplementary  Fig. S2 ), which may be conformers of the tetramer (discussed in ref. 9 ). When all aS-immunoreactive mid-MW bands (60, 80 and 100 kDa) are considered together, the multimer content of cultured cells and brain substantially exceeds the monomer content (2-3:1), as judged by antibodies that react similarly with both. And if some of the aS14 we observe represents 'falsepositive' monomers present because the crosslinking is not fully efficient, then the multimer:monomer ratio in vivo is even higher than 3:1. Whatever the absolute multimer:monomer ratios are in vivo, the consistent detection of multimers of endogenous aS and bS in normal cells by both in situ crosslinking and fluorescence complementation contrasts sharply with the longheld view that cellular aS assemblies above monomer are exclusively pathological.
How can our findings be synthesized into an integrated model for the conversion of physiological aS into pathogenic forms? The field has long accepted that contact between the 'natively unfolded monomer' and negatively charged lipid vesicles in vitro induces a-helical structure 44 . If this finding has any in vivo relevance, we hypothesize that after their synthesis on the ribosome, unfolded aS monomers undergo a helical conversion and multimeric assembly, perhaps by transient contact with lipid vesicles followed by rapid detatchment, thus ending up principally in the cytosol, where we recover the tetramers quantitatively after in vivo crosslinking. Alternatively, an unknown small ligand, for example, a free lipid, could induce and/or maintain the folding and assemby state. Our inability to detect by mass spectrometry any other proteins as a component of the gel-purfied aS60 tetramer does not exclude the presence of one or more lipids in the assembly. Our findings (sequential extractions that leave aS60 principally in the cytosol (Fig. 1a) ; diffuse cytosolic signal of the multimers by YFP complementation (Fig. 1e-g )) argue against a persistent close contact between membranes and most tetramers/multimers at steady state.
Pathological polymerization may occur when the storage capacity of the cell's native tetrameric population is somehow exceeded, for example, destabilization by missense mutations leading to relatively more monomers, or else chronic elevation of all forms of the protein (for example, increased gene dosage 5 ), leading to absolutely more monomers. In sporadic PD, different neuronal stressors could, over time, destabilize a small fraction of the WT tetrameric population to monomers, for example, through post-translational modifications such as phoshorylation, dopamine induced conformational changes, oxidative stress/free radical accumulation with age, chronic mitochondrial dysfunction, altered chaperone systems, metal ion dyshomeostasis, or extraneuronal amyloid-b accumulation (in Alzheimer's disease). In such pathogenic scenarios, which could underlie cases of 'idiopathic' synucleinopathies, pathological aS aggregates would represent a secondary effect, whereas in aS mutation carriers, they would be considered primary.
The drastic alteration in aS multimerization state on cell lysis 9 makes addressing its function challenging. aS cannot be easily studied in its native state outside of cells by conventional biochemical approaches because of the apparent dynamic flux between multimers and monomers that exists in intact cells 9 . Only techniques that reveal the intracellular state of aS and are also sufficiently sensitive to quantify the range of endogenous assembly forms should be used. At present, this means relying on quantifiable in vivo crosslinking with cell-penetrant agents that can trap aS and bS in their native multimeric states, and imaging of intact cells expressing tagged forms, although the latter approach has the twin disadvantages of modifying the aS structure and not distinguishing different-sized multimers. We have reported clear evidence that multi-step purification of endogenous aS from human cells and brain allows a portion of the purified protein to remain tetrameric during the native purification 7, 45 .
The central therapeutic implication of our work is similar to that achieved for transthyretin 46 , a physiological tetramer stabilized by a natural ligand (thyroxin), destabilized by amyloidogenic missense mutations, and therapeutically stabilized by certain small molecules (for example, tafamadis). Similar strategies are being discussed for the cancer-relevant physiological tetramer of p53 (refs 47-49) . The stabilization by small, brain-penetrant molecules of the aS tetramer is now a rational and attractive goal.
Methods
All materials mentioned were purchased from Invitrogen unless stated otherwise. ; age-matched pairs, male, 6-9-week old) from Jackson labs, Bar Harbor, ME. The human cerebral cortex biopsy was obtained fresh from a patient undergoing focal ablative surgery for epilepsy who was otherwise healthy and had no synucleinopathy or other neurodegenerative disease; the sample was obtained from unaffected, discarded tissue and analysed fresh (storage on ice about 2 h).
Cell culture and transfection. Cells were cultured at 37°C in 5% CO 2 . Human erythroid leukemia cells (HEL; ATCC number TIB-180) were cultured in RPMI 1640 (ATCC modification) supplemented with 10% fetal bovine serum (Sigma), 50 units per ml penicillin, and 50 mg ml -1 streptomycin. Human neuroblastoma cells (BE(2)-M17, called M17D; ATCC number CRL-2267) were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 50 units per ml penicillin, 50 mg ml À 1 streptomycin, and 2 mM L-glutamine. M17D cells were transfected using Lipofectamine 2000 according to manufacturer's directions. Cells were normally collected 48 h after transfection. Primary neurons were cultured from E18 Sprague-Dawley rats (Charles River, Wilmington, MA). Rats were euthanized with CO 2 followed by cervical dislocation. Embryonic cortices were isolated and dissociated with trypsin and trituration. Cells were plated in DMEM supplemented with 10% FBS, 50 units per ml penicillin, 50 mg ml -1 streptomycin, and 2 mM glutamine at 680 cells per mm 2 on BioCoat poly-D-lysine-coated culture dishes (BD Biosciences). After 4 h, medium was changed to Neurobasal medium supplemented with B-27, 2 mM GlutaMAX, and 50 mg ml -1 gentamicin. Half of the medium was replaced every 4 days; on the first medium change, 5-fluoro-2-deoxyuridine (Sigma) and uridine (Sigma) were added to concentrations of 100 and 500 mg l -1 , respectively. cDNA cloning. Single-mutation aS expression plasmids were generated from the pcDNA4/aS plasmid 9 using the QuikChange II site-directed mutagenesis kit and appropriate primers. Multiple-mutation constructs were synthesized as GeneArt Strings DNA fragments (GeneArt/Life Technologies), and inserted into pcDNA4 with the In-Fusion HD Cloning Kit (Clontech). pcDNA3/VN-aS and pcDNA3/aS-VC WT and fPD mutant constructs were gifts of T.F. Outeiro, Goettingen). VN and VC constructs for insertion into pcDNA4/TO/myc-his A (pcDNA4) were synthesized by GeneArt, excised directly from the vector in which the constructs were delivered, and ligated into pcDNA4. aS tagged constructs were created by linearizing the resulting construct in pcDNA4 and inserting aS cDNA by InFusion. Full-length YFP was reconstituted from the VN and VC tags and inserting into pcDNA4; full-length tagged constructs were subsequently made by insertion of cDNA upstream of the tag. Lentiviral constructs pLenti6/aS WT, G51D, E46K, 2K and 3K were generated by In-Fusion with the pLenti6 vector and respective cDNA templates. Lentiviral construct pWPXL/aS-WT was generated by In-Fusion from pWPXL/eGFP (pW), a gift of Didier Trono (Addgene plasmid # 12257), without removing eGFP. pCAX/dsRed and pcDNA3.1/Bax were gifts from T. Young-Pearse and M. LaVoie, respectively. The following primers were used. To reconstitute full-length YFP and infused into pcDNA4: VN-to- Stable cell pools and cell lines. Lentiviral particles derived from pLenti6 were generated as recommended by the manufacturer. Lentivral particles derived from pWPXL were generated with plasmids psPAX2 and pMD2.G (also gifts from D. Trono. Addgene plasmids #12260 and 12259, respectively). M17D cells were transduced with viral particles according to the respective recommended protocols. The stable monoclonal cell line M17D/VN-aS was generated by transfection of M17D cells with pcDNA3/VN-aS, followed by G418 selection and isolation of single clones. Stable pools of pLenti6 transduced cells were generated by blasticidin selection, and stable pools of pWPXL transduced cells were selected for residual GFP expression with FACS.
Human ES cell and iPSC cultures. hiPSCs and the hESC lines WIBR3 (Whitehead Institute Center for Human Stem Cell Research, Cambridge, MA) and BG01 (NIH code: BG01; BresaGen, Inc., Athens, GA) were maintained on mitomycin C-inactivated mouse embryonic fibroblast feeder layers in hESC medium (DMEM/ F12 supplemented with 15% FBS (Hyclone), 5% KnockOut Serum Replacement, 1 mM glutamine, 1% nonessential amino acids, 0.1 mM b-mercaptoethanol (Sigma) and 4 ng ml À 1 FGF2 (R&D systems)) 30 . Cultures were passaged every 5-7 days either by trituration or enzymatically with collagenase type IV (Invitrogen; 1.5 mg ml À 1 ).
Gene-edited pluripotent stem cell lines. hESCs lines expressing human aS (WT or hA53T mutant) under the control of Dox from a defined genetic 'safe harbor' locus were generated by a previously described ZFN-based genome-editing strategy. ZFNs were linked to WT FokI which was linked to an obligate heterodimer form of the Fok1 endonuclease (ELD-KKR) 28, 29 . hESCs were simultaneously targeted in both alleles of the AAVS1 locus with two distinct donor plasmids, each containing a distinct selection marker (neomycin or puromycin resistance gene) followed by either a CAGGS promoter driving constitutively expressed reverse tetracycline transactivator (M2rtTA) or the aS transgene (WT or A53T) driven by a Dox-responsive element. Correctly targeted hESC clones derived from individual cells with unique integration of each donor plasmid in one of the AAVS1 alleles and lack of additional random donor integrations were identified by Southern blotting as described 28 . aS expression in NPC was induced by supplementing the medium with Dox at a final concentration of 2 mg ml À 1 . The A53T iPSCs plus genetically corrected isogenic line (WT corr ) as well as the genetically engineered E46K hESC line plus parental WT aS hESC line had been generated before by the ZFN-based genome-editing strategy, as published in detail 30 .
NPC culture and terminal differentiation. Differentiation into NPCs and then terminally differentiated neurons was according to reported protocols with slight modifications 28, 50 . Briefly, hESC/hiPSC colonies were collected using 1.5 mg ml À 1 collagenase type IV, separated from mouse embryonic fibroblast feeder cells by gravity, gently triturated and cultured for 8 days in non-adherent suspension dishes (Corning) in EB medium (DMEM with 20% KnockOut Serum Replacement, 0.5 mM glutamine, 1% nonessential amino acids, 0.1 mM b-ME (Sigma)) supplemented with 50 ng ml À 1 human recombinant Noggin (Peprotech) and 500 nM dorsomorphin (Stemgent). Subsequently, human EBs were plated onto dishes coated with poly-L-ornithine (15 mg ml À 1 , Sigma), laminin (Sigma) and fibronectin (Sigma) in N2 medium supplemented with 50 ng ml À 1 human recombinant Noggin, 500 nM dorsomorphin and FGF2 (20 ng ml À 1 , R&D Systems). After 8 days, neural rosette-bearing embryonic bodies (EBs) were microdissected, dissociated with 0.05% trypsin/EDTA solution and expanded on poly-L-ornithine, laminin and fibronectin coated dishes at a density of 5 Â 10 5 cells per cm 2 in N2 medium supplemented with FGF2 (20 ng ml À 1 ). Proliferating NPCs were passaged 2-3 times before induction of terminal differentiation into neurons by growth factor withdrawal in N2 medium supplemented with ascorbic acid (Sigma). Differentiated neurons were used for chemical crosslinking 45-55 days after induction of terminal differentiation.
Immunocytochemistry. Cells were grown on poly-D-lysine-coated surfaces or coverslips, rinsed twice with HBSS with divalent cations, fixed 25 min at RT with 4% paraformaldehyde/PBS, then washed three times for 5 min with PBS 51 . Cells were then blocked and permeabilized with 5% BSA/0.25% Triton X-100/PBS. Cells were incubated with primary antibody in block-permeabilizing buffer for 2 h at RT or overnight at 4°C. After incubation with primary antibody, cells were washed 3 Â for 5 min with PBS, then incubated 1-2 h at RT with Alexa Fluor 488-and Alexa Fluor 568-coupled secondary antibodies diluted 1:2,000 in 5% BSA/PBS (no Triton). Cells were washed 3 Â 10 min at RT with PBS, then analysed directly in the dish (Fig. 6j ) or after mounting with Mowiol (Sigma) and coverslips (Fig. 1e,f) .
Intact-cell crosslinking of cultured cells. Crosslinkers were stored at 4°C with desiccant. Cells were collected by trituration (HEL and M17D) or scraping (primary neurons), washed with PBS, and resuspended in PBS with Complete Protease Inhibitor, EDTA-free (Roche Applied Science). Crosslinkers were prepared at 50 Â final concentration in DMSO immediately before use. Samples were incubated with crosslinker for 30 min at 37°C with rotation. The reaction was quenched by adding Tris, pH 7.6, at 50 mM final concentration and incubated for 15 min at RT. After quenching, proteins were extracted (see below). Before crosslinking, one representative aliquot of the cells (for example, one extra 6-cm dish cultured for this purpose) was lysed in a volume of PBS/PI that was estimated to generate a protein concentration in the cytosol fraction of 1.5 mg ml À 1 (lysis by sonication; 20,000 g spin, 30 min, 4°C to collect cytosol). Then, the actual protein concentration was determined by BCA assay. On the basis of this result, the final volume of crosslinking buffer (PBS/PI þ 1 mM DSG or 1.75 mM DSP) for all the cell samples was adjusted so as to guarantee a 1.5 mg ml À 1 cytosolic protein concentration in every sample at time of crosslinking. In general, samples with a measured concentration of o1.3 or 41.7 mg ml À 1 were excluded from analyses. As an alternative, samples (for example, cells from one 10-cm dish) were split into different tubes of 1 mM DSG at different volumes (for example, 300, 400, 500 mL), followed by protein extraction, BCA assay and matching of samples that have similar protein concentration as an indication of similar protein-to-crosslinker ratios. The most important criterion for data inclusion was equal crosslinking observed for the DJ-1 control blots (no apparent differences in DJ-1 dimer:monomer ratios was a pre-established criterion 9 ). Before crosslinking and further processing, sample order was randomized.
Intact-cell crosslinking of fresh brain tissue. For intact-cell crosslinking of fresh brain, samples (mouse whole brain, human cortical biopsy) were finely minced by two rounds on a McIlwain Tissue Chopper (model MTC/2E, Mickle Laboratory Engineering Co., Gomshall, UK; blade interval: 100 mm); the sample was turned 90°a fter the first round. Minced samples were transferred to 15 ml tubes containing 5 ml PBS/PI, and the solution was resuspended by gentle shaking. Aliquots were transferred to 1.5 ml tubes and spun at 1,500 g for 5 min at RT. Supernatants were discarded, and the pellets (intact tissue bits) underwent crosslinking routinely at a ratio of 1 ml 1 mM DSG per 100 mg tissue or 1 ml 1.75 mM DSP per 100 mg tissue, while for DSG gradients we used volumes of 0.4-2 ml of 1 mM DSG per 100 mg tissue. The tissue suspensions were incubated at 37°C for 30 min with shaking, followed by spinning at 1,500 g for 5 min at RT. After this intact-cell crosslinking, the supernatant was discarded, and the brain bits in the pellet were resuspended in PBS/PI (in 0.25 ml per 100 mg tissue), followed by protein extraction as described below.
Protein extraction. Cells were lysed by sonication (Sonic Dismembrator model 300; microtip setting ¼ 40; 2 Â 15 s). Spinning at 800 g for 5 min at 4°C yielded the postnuclear supernatant (step was occasionally omitted), and this was centrifuged at 20,000 g for 30 min or ultracentrifuged at 100,000 g for 60 min at 4°C to collect the supernatant ('cytosol') and pellet (membranes). The latter pellet was resolubilized by sonication (2 Â 15 s, amplitude 40) in PBS/1% TX-100 (same volume as cytosols), followed by centrifugation at 20,000 g for 30 min or ultracentrifugation at 100,000 g for 60 min at 4°C. The resultant supernatant contained extracted membrane proteins; in some experiments, we added a 1 h 2% sarkosyl incubation of the TX-100-insoluble or a 4 h incubation of the LDS-insoluble pellet in 88% formic acid with shaking. Cytotoxicity assays. The ToxiLight Non-destructive Cytotoxicity BioAssay Kit (Lonza) was used according to directions to measure adenylate kinase release; signals from untransfected cells were subtracted for normalization. For trypan blue assays, cell suspensions were mixed 1:1 with 0.4% Trypan Blue (Sigma) and counted on a TC10 automated cell counter (Bio-Rad).
YFP complementation and microscopy. The principle of the YFP complementation assay, including controls for the specificity of the VN-aS/aS-VC interaction, has been described 22, 23, 55, 56 . We routinely used a stable cell line M17D/ VN-aS into which we transfected VC-tagged plasmids (1 mg DNA per well of a 24-well dish), followed by automated fluorescence detection (excitation 505 nM, emission 535 nm; Synergy H1 HybridReader, BioTek) 40 h post transfection. Alternatively, we co-expressed a constant WT aS-VC plasmid (4 mg per 6-cm dish) and a variable VN-aS plasmid (WT or point mutants; 2 mg per 6-cm dish) for 40 h in M17D cells followed by bright-field and fluorescence microscopy of live cells in culture dishes (AxioVert 200 microscope; AxioCam MRm camera; AxioVision Release 4.8.2; all by Zeiss, Jena, Germany). Images of YFP were collected using a GFP/FITC filter cube and are pseudo-colored green. GFP detection was enhanced by using an anti-GFP antibody. Microscopy analyses were performed in a blinded fashion by assigning random numbers to culture dishes by one investigator before representative images for each culture were taken or cells ( þ / À inclusions) were counted by another investigator. Confocal images were obtained on a Zeiss LSM710 system.
